INTRODUCTION
Following the success of Glivec in the treatment of chronic myelogenous leukaemia, the development of small molecule kinase inhibitors has become an established goal in drug discovery [1] . A major obstacle is that the ATP-binding pocket, the ubiquitous druggable binding site for inhibitors, is highly conserved across more than 500 human kinases. The rapid growth in the number and chemical variety of kinase inhibitors has been aided by the contribution of structural biology, especially the high-resolution snapshots of kinase/inhibitor complexes captured by X-ray crystallography [1, 2] . These studies revealed the specific conformations recognized by the two main classes of kinase inhibitor. Type I inhibitors recognize the active, typically phosphorylated, form of the kinase, and Type II inhibitors recognize an inactive, typically dephosphorylated, form of the enzyme. In Type I inhibitor co-crystal structures, the conformation of the activation loop, a motif containing the regulatory phosphorylation sites of kinases, adopts the same conformation as that observed in ADP/ATP-bound structures. This conformation is termed DFG-in after the highly conserved aspartic acid-phenylalanine-glycine motif at the N-terminus of the activation loop. In the DFG-in conformation, the aspartic acid side chain points into the active site where it co-ordinates bivalent cations and the phenylalanine side chain points into the interior of the protein. By contrast, Type II compounds stabilize a DFG-out conformation of the activation loop, in which the phenylalanine side chain points outwards and interacts with the compound, and the aspartic acid side chain is displaced away from the active site [3] [4] [5] . Structure-based drug design can be used to develop Type II DFG-out binding compounds based on Type I DFG-in binding precursors [6] . The field is still a long way from the direct rational design of selective and potent kinase inhibitors with a controlled selectivity profile. Currently, multiple iterative design cycles are required to optimize compounds towards the desired biological profile. However, structural biology has provided insight and direction to the design of selective inhibitors that avoid off-target kinases. The selectivity profile of kinase inhibitors is very difficult to explain, even with the help of a high-resolution crystal structure. For example, 9 years after the crystal structure of cAbl bound to a Glivec variant showed that this inhibitor recognizes the DFGout conformation, there is still debate about the structural and thermodynamic basis for its selectivity [3, 7, 8] . It is clear, however, that the cAbl/Glivec variant structure was the inspiration for a new approach to kinase inhibitor design that has yielded many valuable compounds [6] .
Many mitotic kinases are promising cancer drug targets because they are overexpressed in tumours, and their inhibition generates an aberrant cell division that can selectively kill tumour cells [9] . A great deal of attention has been focused on the three Aurora kinases (A, B and C) , and a number of structurally diverse inhibitors have been developed that target this family [10] [11] [12] . The Millennium Pharmaceuticals compound MLN8054 is an Aurora-family-specific inhibitor that inhibits seven out of 226 kinases, more than 50 % at a concentration of 1 μM [13] or has a K d < 100 nM for six out of 317 kinases [14] . Unlike any of the other Aurora inhibitors, MLN8054 is based on a benzazepine scaffold and it has been of considerable interest to determine the binding mode of this compound and shed light on its specificity. MLN8054 is also the first inhibitor discovered to show increased selectivity towards Aurora-A both in a human colorectal tumour cell line and in vitro [13, 14] . Aurora-A is amplified and/or overexpressed in many cancers and cancer cell lines, including hepatocellular carcinoma [15] , breast cancers [16] and neuroblastoma cell lines [16] . Polymorphisms in the Aurora-A gene confer increased breast and colon tumour susceptibility, and somatic mutations in Aurora-A have been identified in colorectal adenocarcinoma, lung carcinoma and melanoma [17, 18] . Inhibition of Aurora-A may be a useful therapeutic strategy in these cancers, and clinical trials of several Aurora inhibitors, including a modified version of MLN8054 (MLN8237), are ongoing.
The selectivity of MLN8054 can be considered as a function of two individual factors: bias towards Aurora-A, and selectivity towards the Aurora family. To investigate the first factor, we have studied the effects of MLN8054 on both Aurora-A and an Aurora-B active-site mimic (AurA x3 ). We find that MLN8054 exhibits a 6-fold stronger inhibition of Aurora-A than AurA x3 in vitro. The crystal structure of AurA x3 bound to MLN8054 exhibits a highly unusual conformation of the activation loop. The characteristic features of the conformation are that both the aspartic acid and phenylalanine residues of the DFG motif point into the interior of the protein structure, and the activation loop wraps around the inhibitor and makes contact using a valine side chain five residues after the start of the DFG motif. The structural details of this conformation, and a comparison of the key residues involved with those found in other human kinases show that it provides a rationale for understanding the selectivity of MLN8054 towards Aurora kinases. The binding of MLN8054 is accompanied by the creation of a hydrophobic pocket equivalent to that filled by the DFG phenylalanine side chain in a DFG-out structure. Our analysis suggests that a subset of kinases could be targeted through the design of inhibitors to fill this pocket, and that this would be an alterative route to producing highly specific compounds.
MATERIALS AND METHODS

Chemical synthesis
MLN8054 was synthesized as described previously [19] .
Protein production and crystallization
The QuikChange ® (Stratagene) method of site-specific mutagenesis was used to produce AurA x3 (L215R, T217E and R220K), AurA TE (T217E) and AurA WL (W277L). AurA (wildtype Aurora-A catalytic domain), AurA x3 , AurA TE and AurA WL proteins were expressed and purified as described previously [20] . Crystals of AurA x3 -MLN8054 were obtained using the hanging drop method of vapour diffusion. For the P3 1 form, the well buffer was 0.8 M NaH 2 PO 4 /1.2 M K 2 HPO 4 and 0.1 M acetate (pH 4.5). For the P6 1 22 form, the well buffer was 0.1 M Mes sodium salt (pH 6.5), 2.0 M ammonium sulfate and 5 % (w/v) PEG400 [poly(ethylene glycol) 400]. Drops comprised a 1:1 ratio of AurA x3 at 7 mg/ml and 1 mM MLN8054 in DMSO. Crystals were briefly soaked in well buffer supplemented with 20 % glycerol (P3 1 ) or 30% glycerol (P6 1 22) before flash freezing in liquid nitrogen.
In vitro kinase assays
Kinase assays were carried out at room temperature (∼ 25
• C) using a Labchip EZ Reader II system (Caliper Life Sciences) and a fluorescein-labelled substrate peptide [5- ). In the experiments to measure the effect of TPX2 (targeting protein for Xenopus Xklp2) on the potency of MLN8054, 3.4 μM TPX2 (residues 1-43) was preincubated with AurA for 10 min before the addition of MLN8054 and substrate. This concentration is 340 times the EC 50 of TPX2, which was determined to be 10 nM under conditions of saturating ATP. All measurements conformed to the linear initial rate assumption and best-fit rates were used to construct rate against [ATP] curves. Data were fitted to a global model for competitive inhibition using Prism5 (http://www.graphpad.com).
Crystallographic data processing and refinement
Diffraction data were reduced using Mosflm, scaled with Scala and the molecular replacement solutions were obtained with Phaser using the structure of ADP-bound Aurora-A as a model [21] . Four AurA x3 molecules were located in the P3 1 asymmetric unit, exhibiting clear difference density corresponding to two different conformations of the activation loop. Co-ordinates and refinement parameter (.cif) files for the MLN8054 ligand were made using Phenix [22] . Iterative cycles of model building and refinement were carried out using Coot and Phenix [21, 22] . All structure figures were produced using PyMOL (http://www.pymol.org).
Sequence analysis of the human kinome
The human ePK (eukaryotic protein kinase) alignment containing 491 kinase domains, available at http://www.kinome.com, was used as the basis for calculating the frequency of amino acids at specific positions within the sequence as shown in Table 3 [23] . The sequence alignment was interrogated using a custom Perl script, available upon request from the corresponding author.
RESULTS
Characterization of an active-site model of Aurora-B
The catalytic domains of human Aurora-A and Aurora-B are 76 % identical at the primary sequence level, and differ by just three amino acids in their ATP-binding pockets: [24] and quinazoline-13 [27] . studies and to assess the contribution of the three residues to the selectivity of MLN8054. The resulting enzyme is catalytically active, with kinetic parameters very similar to those for the wildtype Aurora-A catalytic domain, which we call AurA ( Figure 1a and Table 1 ). MLN8054 acts as an ATP-competitive inhibitor for both enzymes (Lineweaver-Burke plots intersecting on the y-axis; results not shown) and the resultant K i values show a 6-fold discrimination for AurA over AurA x3 , greater than that which can be explained by the relative K m values of the active site for ATP alone. This level of discrimination compares well with the 7-fold difference in dissociation constants reported in the absence of ATP using bead-based competition binding assays [14] , although we report a consistently tighter binding (0.3 nM compared with 6.5 nM, and 1.8 nM compared with 43 nM for Aurora-A and Aurora-B respectively). We have used eqn (1) and our measured K i to calculate the IC 50 we would expect to measure for AurA under the experimental conditions reported for radioactive FlashPlate assays [13] . The calculated value of 3 nM compares very well with the published IC 50 of 4 nM, although we should point out that the extremely tight binding of MLN8054 means that the IC 50 contains a large contribution from the assay enzyme concentration. A similar calculation for Aurora-B using the K i for AurA x3 and a commercially reported K m for Aurora-B (5 μM, http://www.caliperls.com/products/aurb-h.htm) is within a factor of two (calculated 93 nM, reported 172 nM).
We can thus conclude that the three point mutations differentiating AurA x3 and AurA provide a good model for assessing the contribution of active-site residues to the binding of MLN8054. Interestingly, the difference between our measured K m for ATP for AurA x3 (46 μM) and the reported value for AurB (5 μM) means that we would expect additional residues outside the active-site pocket to influence the binding of ATP.
Binding mode of MLN8054 in the active site of Aurora kinase
The chemical structure of MLN8054 is shown in Figure 1 (b). AurA x3 was co-crystallized with MLN8054 and the structure determined to a resolution of 2.4 Å (1 Å=0.1 nm) ( Table 2 ). There are four AurA x3 molecules in the asymmetric unit that adopt two slightly different protein conformations of which chains A and B are representative (Figure 2a ). The two conformations are the result of two different crystal packing contacts between the activation loop and a neighbouring molecule (indicated by stars in Figure 2a ). The structure of the Aurora-A catalytic domain mutated on the two sites of auto-phosphorylation (T287A and 98.4 92.9 †R-free was computed using 5 % of the data assigned randomly.
T288A), which we shall refer to as AurA AA , bound to the 8054-like compound (shown in Figure 1b ) has recently been determined (PDB code 3H10, [24] ). This complex crystallized in a different crystal form (P2 1 2 1 2 1 ) to the AurA x3 -MLN8054 (P3 1 ). In chains A and B of this structure the activation loop of AurA AA has a very similar conformation to that found in chain B of the AurA x3 -MLN8054 structure and is involved in different crystal packing contacts (Figure 2a) . The activation loop is disordered between residues 284-291 in the third chain (D) of the AurA AA /8054-like structure, which presumably cannot form a stabilizing crystal packing contact.
Additional electron density within the active site of AurA x3 was very clear, and the MLN8054 ligand was fitted unambiguously (Figure 2b ). The two different conformations of AurA x3 are in fact very similar in the vicinity of MLN8054, with the exception of residue Glu 217 , one of the residues mutated to mimic Aurora-B. In chain A Glu 217 is closest to the benzoic acid moiety of MLN8054 (3.8 Å is the shortest interatomic distance), whereas in chain B Glu 217 is closest to the difluorophenyl group (4.7 Å is the shortest interatomic distance). The active site of AurA AA bound to the 8054-like compound is very similar in all three chains and is very similar to that of either of the two chains of AurA x3 bound to MLN8054 (Figure 2b ). In the structure of AurA AA -8054-like, the methyl group of Thr 217 is closest to the difluorophenyl group (3.6-3.8 Å). The substitution of glutamate for threonine at position 217 has no effect on the binding mode. However, the individual T217E point mutant of Aurora-A (AurA TE ) is almost 20-fold less potently inhibited by MLN8054 than the wild-type AurA ( Figure 1 and Table 1 ). The difference in potency of MLN8054 inhibition between AurA and AurA x3 is therefore primarily due to the T217E mutation. The difference is modest because there is no steric clash and hence no change in binding mode, and the flexibility of the Glu 217 side chain reduces the effectiveness of the repulsion between the ionized glutamate residue and the hydrophobic difluorophenyl or benzoic acid groups of MLN8054. (Figure 2c ). The aromatic benzoic acid group sits above the C α of Gly 216 in a position similar to that occupied by aromatic rings in other Aurora inhibitor structures (e.g. PDB codes 2BFY [25] and 2W1I [26] ). The chlorine atom and the aromatic ring to which it is attached pack against the glycine-rich loop. The difluorophenyl group packs against Leu 263 , Ala 273 and Val 279 , which also packs against the chlorine atom. With the exception of the acidic group, the entire molecule of MLN8054 is buried inside the active-site pocket of AurA x3 . Remarkably, this is achieved in part by the remodelling of the activation loop conformation to wrap around part of the inhibitor.
The conformation of the activation loop induced by binding of MLN8054
The conformations of the activation loop adopted by AurA x3 bound to MLN8054 and AurA AA bound to the 8054-like compound are highly unusual. The activation loop is flipped around compared with the DFG-in conformation observed in the ADP-bound AurA structure [20] and superficially resembles a DFG-out conformation, as observed in AurA-quinazoline-13 or cAbl bound to a Glivec variant (Figure 3a , PDB codes 2C6E and 1FPU respectively [3, 27] ). Upon closer inspection, the conformation of the activation loop of AurA x3 -MLN8054 is clearly different. In DFG-in and DFG-out conformations of kinases, the aspartic acid and phenylalanine side chains sit on opposite sides of the backbone. In these conformations, when the phenylalanine side chain points into the interior of the protein, the aspartic acid side chain points out into the active site and vice versa (Figure 3b ). By contrast, in the AurA x3 -MLN8045* and AurA AA -8054-like structures, both Asp 274 and Phe 275 project up into the interior of the kinase (Figures 3b and 3c ). For this reason, and for the sake of brevity, we shall refer to this conformation as DFG-up.
The DFG-up conformation is characterized by a substantial reorganization of the activation loop between residues 274-293 and the HRD motif at residues His 254 and Arg 255 . Compared with the DFG-in conformation, the side chain of Asp 274 is rotated by approx. 180
• so that it points into the interior of the protein, parallel to helix αC (Figure 3b inwards and interacts with Asp 274 (DFG motif) and Asn 185 (helix αC), whereas it normally faces outwards, and recognizes the phosphorylated Thr 288 in an active AurA structure (PDB code 1OL5 [20] ).
The DFG-up conformation is distinct from the DFG-out conformation that is observed in the structures of quinazoline-13 bound to Aurora-A or a Glivec variant bound to cAbl. Apart from the differences in the DFG motif, in the DFG-out conformation Trp 277 interacts with the quinazoline-13 inhibitor and the arrangement of the HRD motif is similar to that found in the DFG-in conformation. Additionally, structures of Aurora-A and cAbl in the DFG-out conformation are of dephosphorylated kinases, whereas the DFG-up is observed with either phosphorylated or unphosphorylated Aurora-A. We speculate that phosphorylated Aurora-A can adopt DFG-up (and probably DFG-out) conformations without much energetic penalty because the phosphorylated activation loop of Aurora-A is not stably locked in the active conformation except in the presence of TPX2 [20] . One prediction from the AurA x3 -MLN8054 structure is that the binding of TPX2 should decrease the potency of MLN8054 either through competition or because more energy is required to move the activation loop from its stable active conformation into DFG-up. We determined the K i for MLN8054 for AurA in the presence of a saturating concentration of TPX2 to be 3.3 + − 0.2 nM, a substantial increase on the K i in the absence of TPX2 comparable with that obtained with AurA x3 or AurA TE (Table 1 , and Supplementary Figure S1 and Supplementary Table  S1 at http://www.BiochemJ.org/bj/427/bj4270019add.htm).
Insights into the selectivity of MLN8054 for Aurora kinases
Close inspection of the structure shows that many of the interactions between residues proximal to the active site are rearranged with respect to previous Aurora-A structures. This observation led us to consider whether other kinases might be able to adopt a similar conformation and if this might have any bearing on the selectivity of MLN8054. A search of the published alignment of human kinases and a search using the ProSite server reveals that only Aurora kinases possess a tryptophan residue at the equivalent position to 277, three residues after the start of the DFG motif (D + 3; Table 3 ) [23] . Most of the more frequent residues at this position are hydrophobic and could not form an H-bond with Glu 181 . The exception to this is serine, found in 7.5 % of kinases, although the position of the side chain would have to be shifted by 2 Å to make the H-bond. Figure S1 and Supplementary Table S1 ). This supports our suggestion that the unusual tryptophan residue at position 277 contributes to MLN8054 selectivity towards Aurora kinases. Val 279 at D + 5 is also unusual at its position in the kinase domain and is found in less than 5 % of kinases (Table 3 ). In most kinases that are regulated by phosphorylation of the activation loop the equivalent residue at this sequence position is most frequently a lysine or arginine, which interacts with the (3) Leu (16) activating phosphate group (i.e. on a residue equivalent to Thr 288 ) and helps order the activation loop. Full ordering of the activation loop of Aurora-A proceeds by a different mechanism than most kinases because binding of an activator such as TPX2 is required in addition to phosphorylation on Thr 288 [20] . The interior surface of Aurora kinases that is contacted by the DFG motif in the DFG-up conformation is highly unusual. In most kinases, this region is hydrophobic, and in particular there is a conserved hydrophobic residue on the αC helix that forms part of the hydrophobic spine of kinases and interacts with the phenylalanine side chain of the DFG motif in the DFG-in conformation [28] . Across all human kinases, this residue is a leucine in 53 % of cases, and a methionine in 25 %. In the Aurora family, this hydrophobic residue is replaced by Gln 185 , which makes an H-bond with the backbone at Leu 194 . The presence of Gln 185 is presumably important for the DFGup conformation because it lies at the centre of a network of polar interactions that involves the side chains of Asp 274 , Arg 255 and the backbone at Leu 194 . Only COT (cancer osaka thyroid), a mitogen-activated protein kinase kinase kinase, has both equivalent identical residues with Gln 185 and Val 279 , and no other kinase has even a related combination (isoleucine or leucine for valine, and histidine or asparagine for glutamine). The Aurora family thus has a unique set of features that create the capacity to adopt the MLN8054-bound activation loop conformation: the presence of the polar back pocket, the lack of a basic residue at D + 5 and the tryptophan residue at D + 3. This suggests that the conformation of AurA x3 bound to MLN8054 might not be easily accessible to other kinases, and might thus contribute to the selectivity of MLN8054. We obtained a second crystal structure of the complex at 3.3 Å resolution (AurA x3 -MLN8054*) in a P6 1 22 crystal form that is very commonly obtained with AurA (Table 2) . In this structure, the activation loop adopts a DFG-in conformation (Figures 4a and  4b ). This may simply represent a crystallization artefact, because the crystal packing is incompatible with the DFG-up conformation of the activation loop, which appears to be trapped in the DFGin conformation by crystal packing contacts. When compared with the ADP-bound AurA structure, there is a steric clash between the glycine-rich loop in the ADP-bound conformation and MLN8054 (indicated by a star in Figure 4b ). In the AurA x3 -MLN8054* structure the glycine-rich loop is displaced upwards owing to contacts between MLN8054 and the glycine-rich loop at the side chain at Val 147 and the main chain at residues 140-141 (Figure 4b ). The AurA x3 -MLN8054* structure shows that the MLN8054 can be accommodated in the active site without movement of the activation loop, but requires displacement of the glycine-rich loop. Superposition of the higher resolution AurA x3 -MLN8054 or AurA AA -8054-like structures show the same steric clash between the glycine-rich loop of the ADP-bound structure with MLN8054 and a second steric clash between the glycinerich loop of the ADP-bound structure (at residues 142-143) with the activation loop of the MLN8054-bound structure at Val 279 ( Figure 4c) . The higher resolution structures show a displacement of the glycine-rich loop similar to that observed at low resolution in the AurA x3 -MLN8054* structure. It appears that the upwards movement of the glycine-rich loop is a necessary adjustment to accommodate the activation loop in the DFG-up conformation, and could be an initial first step upon binding of MLN8054 to Aurora-A.
The fact that the DFG-up conformation has not been reported before suggested to us that there is something unusual about the binding of MLN8054 that induces this conformation. The superposition of AurA-ADP with AurA x3 -MLN8054 shows that the difluorophenyl group of MLN8054 occupies the equivalent space to that occupied by the α-PO 4 group of ADP, which we shall refer to as the α-PO 4 space (Figure 4d ). The two groups have vastly different chemical properties, and the properties of this space are altered between DFG-in and DFG-up conformations. In the DFG-in conformation, Asp 274 sits to one side of the α-PO 4 space and together with Asn 261 co-ordinates two bivalent cations (e.g. Mg 2 + ) that stabilize the ADP/ATP phosphates. In the DFG-up conformation, Asp 274 is flipped and the Mg 2 + -binding sites are eliminated. The movement of Val 279 completes the conversion of the α-PO 4 space into a hydrophobic pocket, which is occupied by the difluorophenyl group of MLN8054 (Figures 3b and 4d) . The DFG-up conformation of Aurora-A could therefore be driven by the occupation of the α-PO 4 space by the difluorophenyl group of MLN8054. Interestingly, a similar change to the chemical properties of the α-PO 4 space occurs in the DFG-out conformation. In fact, the DFG-up and DFG-out conformations are clearly related and they possess two equivalent hydrophobic pockets that can be filled by a phenyl group (yellow and green broken circles, Figure 4e ). The groups which occupy these two pockets in the DFG-up or DFG-out conformations display a degree of symmetry. In the DFG-out conformation, the α-PO 4 space is occupied by the Phe 275 side chain and the second pocket is filled by the quinazoline-13 compound (Figures 3b and  4e ). In the DFG-up conformation, the α-PO 4 space is occupied by the difluorophenyl group of MLN8054 and the second pocket is filled by the side chain of Phe 275 . Further exploration of the chemical, structural and biophysical relationship between these two conformations may be beneficial in the production of more selective Aurora compounds.
DISCUSSION
The observation of the same unusual activation loop conformation induced by two similar compounds bound to variants of the protein which are unphosphorylated (AurA AA ) or phosphorylated with mutations in the active site (AurA x3 ), and which were crystallized in two different crystals forms, is strong evidence that this conformation is neither an artefact of any of the protein modifications nor an artefact of crystal packing, but is driven by binding of the MLN8054/8054-like compounds. This raises the concern that selectivity testing for MLN8054 may be difficult to interpret because the inhibitor might be expected to bind more tightly to off-target kinases in the inactive state rather than the active proteins which are used in assay screens. Our analysis of the sequence requirements for the DFG-up conformation raises the question of how MLN8054 is able to inhibit several other kinases, albeit with lower potency than the Aurora family, such as Abl (76 % inhibition at 1 μM) and Yes (80 % inhibition at 1 μM) [13] . It is possible that these kinases are able to adopt the DFG-up conformation, and that the lower potency is partly because this conformation is a less favoured, higher energy state. Alternatively, MLN8054 could bind to these kinases in a different conformation, such as the DFG-in conformation observed in the low-resolution AurA x3 -MLN8054* structure. The determination of the selectivity profile of this class of inhibitor is therefore perhaps most accurately achieved by using a direct binding screen against inactive and active forms of the kinases [14] .
Rational design and prediction of selectivity profiles remains an extremely difficult challenge given the existence of multiple inactive conformations accessible to protein kinases and the possibility that some compounds might be able to target more than one conformation.
It has been suggested that Thr 217 might be the basis for the higher potency of MLN8054 for Aurora-A over Aurora-B [24] . We have now confirmed that Thr 217 is the main determinant of its bias towards Aurora-A in vitro and shown the relative disposition of a glutamic acid side chain at this position in the crystal stucture. MLN8054 does not fully utilize the potential of the T217E substitution to generate selectivity, because the compound does not sit very close to residue 217 and can still be accommodated when the residue is substituted for glutamic acid. The selectivity of MLN8054 for Aurora-A over Aurora-B in vitro is not high, only approx. 6-fold using strictly comparable K i or K d measurements. In contrast, MLN8054 is over 100-fold selective for Aurora-A over Aurora-B in cell-based assays, and the compound can be used to obtain a cellular phenotype consistent with clear discrimination [13, 29] . The Aurora-A activator TPX2 reduces the potency of MLN8054 compared with Aurora-A, although only a specific pool of Aurora-A localized to mitotic spindle microtubules is thought to be bound to TPX2. The cellular potency of Aurora-A might be due to targeting the non-TPX2-bound pool of Aurora-A. The mechanism by which Aurora-B is only poorly inhibited by MLN8054 in cells is presently unclear. It is possible that Aurora-B is prevented from adopting the DFG-up conformation through binding to a protein partner, but it is not obvious how this could be mediated from current structures of the Aurora-B-INCENP (inner centromere protein) complex. The elucidation of this mechanism may be important for understanding the cellular regulation of these kinases.
The structure of AurA x3 bound to MLN8054 suggests that the specificity of this compound for the Aurora family is at least partly a function of the protein conformation it induces. This does not imply that we believe it to be impossible to produce inhibitors that target other kinases in a DFG-up conformation. On the contrary, it might be possible to exploit the principle behind the DFG-up conformation to generate compounds that induce the DFG-up conformation of other kinases, just as it has been possible to generate potent inhibitors that bind the DFG-out conformation of a number of kinases. This is because the conformation induced by these compounds would be DFG-up, but would differ in the precise details of the conformation adopted by the activation loop, especially the residues just after the DFG motif. One feature that is potentially vital for adopting a DFG-up conformation is the polar residue on the C-helix (Gln 185 ), and an equivalent polar residue is present in just under 10 % of human kinases. We predict that these would be the most likely targets for DFG-up inhibitors. The other key features of the DFG-up conformation are the interactions within the kinase domain and between the activation loop at D + 5 (Val 279 ) and the inhibitor. To design a DFG-up-targeting inhibitor, we predict that one should modify a Type I inhibitor with the addition of a hydrophobic group to fit the α-PO 4 pocket that is complementary to the residue at D + 5. One might expect that this would only work with kinases that possess residues at D + 3 and D + 4 capable of making compensating interactions with the disrupted lysine-glutamate salt bridge residues. Future studies will elaborate which other kinases can be induced to form the DFG-up conformation. Furthermore, the discovery of the DFG-up conformation, and our recent discovery of multiple, stable, ligand-induced conformations of Nek2 kinase [30] suggest to us that the conformational space of the activation loop should be further explored, and exploited to produce selective inhibitors.
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